iCubate is a molecular diagnostic company providing accurate and affordable syndromic testing to clinical laboratories. With FDA cleared, multiplexed, sample in-answer out assays, iCubate offers laboratories of any size an integrated, intuitive, comprehensive solution for the detection and identification of potentially pathogenic gram positive and gram negative organisms associated with bloodstream infection (BSI) and subsequent sepsis. iCubate’s cost-effective assays also detect important gene markers, specific to emerging antibiotic resistance. This provides actionable information that can guide in the early choice of appropriate antimicrobial therapy, resulting in better patient care, shortening hospital stays, reducing costs and benefiting antimicrobial stewardship programs. iCubate is proud to join the fight against BSI and sepsis, an unpredictable condition that is the 10th leading cause of death in the U.S., responsible for more than $16B in direct healthcare costs annually.
Business Needs: Direct Sales, Distributor/Agent/Representative, Investor
Products to be exported: CE IVD Marked products for Bloodstream Infection detection.
Countries of Interest: Belgium, Brazil, Canada, France, Germany, India, Ireland, Israel, Italy, Kuwait, Mexico, Netherlands, Oman, Saudi Arabia, Spain, Taiwan, United Arab Emirates, United Kingdom, United States